FORT MILL, S.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced that the recent addition of key ablation procedures to ambulatory surgery centers (ASC) by Centers for Medicare and Medicaid services (CMS) provides a unique and new opportunity to expand the commercialization of LockeT. In a recent announcement by Heart Rhythm Ad ...

First-ever multi-year agreement highlights commitment to French electrophysiology marketFORT MILL, S.C., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announces its third VIVO™ system installation in France, at the prestigious Centre Hospitalier Régional Universitaire (CHRU) Nancy. Led by Prof. Christian de Chillou, a renowned expert in ...

Core Insights - Catheter Precision, Inc. has received notification from the United States Patent and Trademark Office regarding the allowance for two new patents, enhancing its intellectual property portfolio in the cardiac electrophysiology market [1][4]. Patent Details - The first patent is titled "Methods of Ventricular Arrhythmia Localization Using a 3D Model," which will be assigned to Kardionav, a joint venture aimed at developing new applications for cardiac ventricular therapies [2]. - The second patent, "Neurostimulation Devices and Methods," focuses on improving cardiac ventricular function, particularly for heart failure patients, and will be assigned to Cardionomix, a subsidiary of Catheter Precision [3]. Company Overview - Catheter Precision is a U.S.-based medical device company dedicated to innovating solutions for cardiac arrhythmias, emphasizing collaboration with physicians and continuous product advancement [6]. - The company's VIVO technology is a non-invasive 3D imaging system that helps identify the origins of ventricular arrhythmias before procedures, thereby improving workflow and reducing procedure time [5].

Core Insights - Catheter Precision, Inc. has received its first European purchase order for its product LockeT, marking a significant milestone in its market expansion efforts [1][3] - The successful evaluation of LockeT in Italy follows its acceptance in France and Germany, indicating strong clinical value and versatility [2][4] - The product is designed to assist in wound closure after percutaneous venous punctures and has received both FDA registration and CE Mark approval [4] Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for cardiac arrhythmias, particularly in the electrophysiology market [5] - The company collaborates with physicians to continuously advance its product offerings [5] Product Details - LockeT is a suture retention device aimed at streamlining closure after catheter ablation procedures while being cost-effective [4] - The device is classified as Class 1 and is registered with the FDA, having also received CE Mark approval [4]

Core Viewpoint - Catheter Precision, Inc. has received a new patent for its VIVO technology, enhancing its intellectual property portfolio and supporting its mission to improve non-invasive identification of ventricular arrhythmias [1][2]. Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for cardiac arrhythmias, emphasizing collaboration with physicians and continuous product advancement [4]. Product Information - VIVO (View Into Ventricular Onset) is a non-invasive 3D imaging system that helps physicians identify the origin of ventricular arrhythmias before procedures, thereby improving workflow and reducing procedure time. It has received marketing clearance from the U.S. FDA and holds the CE Mark [3]. Patent Significance - The newly granted patent titled "Methods of Ventricular Arrhythmia Localization Using a 3D Heart Model" allows the company to further advance its identification methods, providing essential information to physicians for successful patient treatment [1][2].

Core Insights - Catheter Precision, Inc. has initiated the LockeT Compare Study, enrolling its first three patients, aimed at evaluating the safety profile of the LockeT suture retention device [1][2] - The study will enroll up to 100 patients and compare the LockeT device with internal closure devices, focusing on reducing groin complications post-cardiac catheter procedures [2] - The LockeT device has shown clinical data indicating safety, effectiveness, and cost reduction without altering hospital practices [2][3] Company Overview - Catheter Precision is a U.S.-based medical device company dedicated to improving cardiac arrhythmia treatment through innovative technology and collaboration with physicians [4] - The LockeT device is a Class 1 device registered with the FDA and has received CE Mark approval, designed for wound closure after percutaneous venous punctures [3][4]

Heart Hospital of New Mexico is the First Hospital to Complete 200 Ventricular Ablation Procedures with the VIVO System FORT MILL, S.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that the Heart Hospital of New Mexico is the first customer to complete 200 ventricular ablation procedures using its VIVO system. Heart Hospital of Ne ...

Core Insights - Catheter Precision, Inc. has received CE Mark approval for its advanced vascular closure device, LockeT, allowing it to enter European markets [2][3] - The European Vascular Closure Devices Market is projected to grow from $3.1 billion in 2024 to $4.3 billion by 2028, with a CAGR of 7% from 2023 to 2028 [3] - The company has already received its first order for 100 units of LockeT, indicating strong initial demand [1][4] Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for cardiac arrhythmias and electrophysiology procedures [6] - LockeT is a Class 1 device designed for wound closure after percutaneous venous punctures and has received both FDA registration and CE Mark approval [5] Market Strategy - The company is actively engaging with distribution partners to market LockeT in newly accessible countries following CE Mark approval [4] - The CEO emphasized the economic advantages of LockeT compared to competitors, highlighting its ease of deployment and patient comfort [4]